Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

Theranostics is the highly targeted molecular imaging and therapy of tumors. Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers. Metastatic, well-differentiated gastroenteropancreatic neuroend...

Descripción completa

Detalles Bibliográficos
Autores principales: Grey, Neil, Silosky, Michael, Lieu, Christopher H, Chin, Bennett B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099199/
https://www.ncbi.nlm.nih.gov/pubmed/35633909
http://dx.doi.org/10.3748/wjg.v28.i17.1768
_version_ 1784706551108337664
author Grey, Neil
Silosky, Michael
Lieu, Christopher H
Chin, Bennett B
author_facet Grey, Neil
Silosky, Michael
Lieu, Christopher H
Chin, Bennett B
author_sort Grey, Neil
collection PubMed
description Theranostics is the highly targeted molecular imaging and therapy of tumors. Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers. Metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors may be most effectively imaged and treated with DOTATATE ligands. We review the current practice, safety, advantages, and limitations of DOTATATE based theranostics. Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics.
format Online
Article
Text
id pubmed-9099199
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-90991992022-05-26 Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors Grey, Neil Silosky, Michael Lieu, Christopher H Chin, Bennett B World J Gastroenterol Minireviews Theranostics is the highly targeted molecular imaging and therapy of tumors. Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers. Metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors may be most effectively imaged and treated with DOTATATE ligands. We review the current practice, safety, advantages, and limitations of DOTATATE based theranostics. Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics. Baishideng Publishing Group Inc 2022-05-07 2022-05-07 /pmc/articles/PMC9099199/ /pubmed/35633909 http://dx.doi.org/10.3748/wjg.v28.i17.1768 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Grey, Neil
Silosky, Michael
Lieu, Christopher H
Chin, Bennett B
Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
title Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
title_full Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
title_fullStr Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
title_full_unstemmed Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
title_short Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
title_sort current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099199/
https://www.ncbi.nlm.nih.gov/pubmed/35633909
http://dx.doi.org/10.3748/wjg.v28.i17.1768
work_keys_str_mv AT greyneil currentstatusandfutureoftargetedpeptidereceptorradionuclidepositronemissiontomographyimagingandtherapyofgastroenteropancreaticneuroendocrinetumors
AT siloskymichael currentstatusandfutureoftargetedpeptidereceptorradionuclidepositronemissiontomographyimagingandtherapyofgastroenteropancreaticneuroendocrinetumors
AT lieuchristopherh currentstatusandfutureoftargetedpeptidereceptorradionuclidepositronemissiontomographyimagingandtherapyofgastroenteropancreaticneuroendocrinetumors
AT chinbennettb currentstatusandfutureoftargetedpeptidereceptorradionuclidepositronemissiontomographyimagingandtherapyofgastroenteropancreaticneuroendocrinetumors

Ejemplares similares